2021-05-10 14:35:39 GMT2021-05-10 22:35:39(Beijing Time) Xinhua English
BERLIN, May 10 (Xinhua) German biotechnology company BioNTech SE said on Monday that it would establish its first hub in the Asia-Pacific region by establishing a regional headquarters in Singapore.
BioNTech also announced that it will build a fully integrated mRNA manufacturing facility in Singapore, supported by the Singapore Economic Development Board (EDB). The facility would be operational in 2023, according to the company. Having multiple nodes in our production network is an important strategic step in building out our global footprint and capabilities, said Ugur Sahin, chief executive officer (CEO) and co-founder of BioNTech, in a statement.
HOT PORT NEWS from GAC
Revision of number of persons onboard pleasure craft
Monday, May 10, 2021, Singapore
This Port Marine Circular updates the number of persons allowed onboard pleasure craft from 8 May to 30 May 2021.
All pleasure craft operators, owners and masters are reminded to ensure that they comply with the measures stipulated in the COVID-19 (Temporary Measures) (Control Order) Regulations 2020, and implement these measures in relation to persons boarding and on the craft.
These measures include implementing contact tracing procedures such as TraceTogether-only SafeEntry (TT-only SE) for all persons who board the pleasure craft. If TT-only SE is not implemented, the craft owner/operator/master must maintain a record of the passenger and crew manifest. Persons onboard should be encouraged to install and use the TraceTogether application or token. In addition, temperature screening and checks on visible respiratory symptoms must be conducted before any person boards th
Fosun, BioNTech in $200 Million China Vaccine Venture
Fosun Pharma announced that it plans to set up a joint venture with German vaccine company Biontech to achieve commercial local production of mRNA neocoronal vaccine products, with an annual capacity of 1 billion doses, on May 9.
Fosun Pharma announced it would set up a Shanghai facility to co-produce a Covid-19 vaccine developed by BioNTech SE for the China market, just hours before the German drug maker announced its own plans to build a regional headquarters and similar wholly owned facility in Singapore.
Announcement of the Shanghai facility marks the latest step in a partnership formed by Fosun and BioNTech early in the pandemic, with an aim of bringing the German company’s innovative and highly effective mRNA vaccine technology to China. Establishment of the Singapore hub is also a nod to the region’s big growth potential, and the importance of producing BioNTech’s vaccines as close as possible to their actual plac
Published: May 10, 2021
BioNTech to establish first regional hub in Asia Pacific region in Singapore
Planned state-of-the-art manufacturing site will support global supply of mRNA-based vaccines and therapeutics and provide a rapid response capability for south east Asia against potential future pandemic threats
Expansion plan supported by the Singapore Economic Development Board (EDB)
MAINZ, GERMANY, May 10, 2021
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced plans to expand its global footprint to Asia with the establishment of its Regional Headquarters for south east Asia in Singapore. In addition to selecting Singapore as its future regional headquarters, BioNTech plans to establish a fully integrated mRNA manufacturing facility in Singapore with support from the Singapore Economic Development Board. The new facility will provide regional and global supply capacity of BioNTech’s growing pipeline of mRNA-based product candidates, a
BioNTech to set up mRNA vaccines manufacturing site in Singapore
The biotech company said the Singapore production facility will have an estimated annual capacity of several hundred million doses of mRNA-based vaccines depending on the specific type, once it is operational in 2023
Reuters | May 10, 2021 | Updated 14:39 IST
BioNTech said on Monday it plans to set up a regional headquarters and build a new manufacturing site for its vaccines based on messenger RNA technology (mRNA) in Singapore, in the latest move to expand its production network.
The biotech company said the Singapore production facility will have an estimated annual capacity of several hundred million doses of mRNA-based vaccines depending on the specific type, once it is operational in 2023.